You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKesson
Colorcon
Dow
Johnson and Johnson
Express Scripts

Last Updated: September 28, 2020

DrugPatentWatch Database Preview

Patent: 8,637,475

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,637,475
Title:Modified 2\' and 3\' nucleoside prodrugs for treating flaviviridae infections
Abstract: 2\' and/or 3\' prodrugs of 1\', 2\', 3\' or 4\'-branchednucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and other related conditions. Compounds and compositions of the prodrugs of the present invention are described. Methods and uses are also provided that include the administration of an effective amount of the prodrugs of the present invention, or their pharmaceutically acceptable salts or derivatives. These drugs may optionally be administered in combination or alteration with further anti-viral agents to prevent or treat Flaviviridae infections and other related conditions.
Inventor(s): Storer; Richard (Kent, GB), Gosselin; Gilles (Monpellier, FR), Sommadossi; Jean-Pierre (Cambridge, MA)
Assignee: Idenix Pharmaceuticals, Inc. (Cambridge, MA) University of Cagliari (Cagliari, IT) The Centre National de la Recherche Scientifique (Paris, FR) L\'Universite Montpelier II (Montpelier, FR)
Application Number:13/168,895
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,637,475
Patent Claims:see list of patent claims

Details for Patent 8,637,475

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Biogen AVONEX interferon beta-1a VIAL 103628 001 1996-05-17   Start Trial Idenix Pharmaceuticals, Inc. (Cambridge, MA) University of Cagliari (Cagliari, IT) The Centre National de la Recherche Scientifique (Paris, FR) L\'Universite Montpelier II (Montpelier, FR) 2022-06-28 RX search
Serono Inc REBIF interferon beta-1a SYRINGE 103780 001 2002-03-07   Start Trial Idenix Pharmaceuticals, Inc. (Cambridge, MA) University of Cagliari (Cagliari, IT) The Centre National de la Recherche Scientifique (Paris, FR) L\'Universite Montpelier II (Montpelier, FR) 2022-06-28 RX search
Serono Inc REBIF interferon beta-1a SYRINGE 103780 002 2002-03-07   Start Trial Idenix Pharmaceuticals, Inc. (Cambridge, MA) University of Cagliari (Cagliari, IT) The Centre National de la Recherche Scientifique (Paris, FR) L\'Universite Montpelier II (Montpelier, FR) 2022-06-28 RX search
Vidara Therapeutics Research Ltd ACTIMMUNE interferon gamma-1b VIAL; SINGLE-USE 103836 001 1999-02-25   Start Trial Idenix Pharmaceuticals, Inc. (Cambridge, MA) University of Cagliari (Cagliari, IT) The Centre National de la Recherche Scientifique (Paris, FR) L\'Universite Montpelier II (Montpelier, FR) 2022-06-28 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
McKesson
Johnson and Johnson
Colorcon
Merck
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.